García RS, Salinas LC, Tena SML,Gómez LMA, Rembao BD

Language: Spanish
References: 23
Page: 228-236
PDF size: 529.69 Kb.

ABSTRACT

Background: Germinal tumors of central nervous system are rare; they are usually located in the middle line. Germinomas are the most common type followed by teratomas. Objective: To know frequency of adults’ intracranial germinal tumors at Instituto Nacional de Neurologia y Neurocirugia, during a ten year surgery period, and to associate histological type with immunohistochemistry markers expression. Material and method: Retrospective, observational, descriptive, histopathological and immnunohistochemical analysis of germinal tumors of the CNS, based on a ten year experience within Neuropathology Department at Instituto Nacional de Neurologia y Neurocirugia. Out of 9,850 brain tumours operated there were 24 cases of germinal tumors (incidence of 0.24%); 18 germinomas and six teratomas; 18 were males, age range was 16 to 44 years (mean: 22.2); 12 cases were located in the pineal gland, three in the thalamus, three in the spinal cord, three in the sellar region, and three in the posterior fossa.Results: Alphfetoprotein was positive in seven cases (29%); βGCH was positive in five (21%); PLAP immunoreaction in 14 (58%); ACE in six (25%). Oncogene BAX was expressed in 19 (79%) cases and Bcl-2 in five (21%). There was no statistical significance between immnunohistochemical reaction for βHGC, AFP, ACE and FAP, and age, gender, tumor location Bcl-2 or BAX expression. Clinically there was statistical significance between age with PLAP (p = 0.004), BAX surgical immunoexpression (p = 0.004), and atypia, pleomorfism and necrosis (p = 0.000). Conclusion: Immunoexpression of those markers could be helpful as biological prognostic predictor.

REFERENCES

1. Jennings MT, Gelman R, Hochberg F. Intracranial germcell tumors: natural history and pathogenesis. J Neurosurg 1985;63(2):155-67.

2. Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumors of the Nervous System. The World Health Organization classification of tumours. Lyon: IARC Press, 2000.

3. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, et al.Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol 1999;1(1):14-25.

4. Baumgartner JE, Edwards MS. Pineal tumors. Neurosurg Clin N Am 1992;3(4):853-62.

5. Regis J, Bouillot P, Rouby-Volot F, Figarella-Branger D, et al.Pineal region tumors and the role of stereotactic biopsy: review of the mortality, morbidity, and diagnostic rates in 370 cases. Neurosurgery 1996;39(5):907-12.

6. Rosemblum MK. Germ cell tumors. In: Bigner DD, McLendon RE, Bruner JM, eds. Russell & Rubinstein´s Pathology of tumors of the nervous system. 7th ed. Oxford: Oxford University Press, 2006;pp:551-78.

7. Huh SJ, Shin KH, Kim IH, Ahn YC, et al. Radiotherapy of intracranial germinomas. Radiother Oncol 1996;38(1):19-23.

8. Haddock MG, Schild SE, Scheithauer BW, Schomberg PJ.Radiation therapy for histologically confirmed primary central nervous system germinoma. Int J Radiat Oncol Biol Phys 1997;38(5):915-23.

9. Sawamura Y, de Tribolet N, Ishii N, Abe H. Management of primary intracranial germinomas: diagnostic surgery or radical resection? J Neurosurg 1997;87(2):262-6.

10. Shirato H, Nishio M, Sawamura Y, Myohjin M, et al. Analysis of long-term treatment of intracranial germinoma. Int J Radiat Oncol Biol Phys 1997;37(3):511-5.

11. Sugiyama K, Uozumi T, Arita K, Kiya K, et al. Clinical evaluation of 33 patients with histologically verified germinoma. Surg Neurol 1994;42(3):200-10.

12. Calaminus G, Bamberg M, Baranzelli MC, Benoit Y, et al.Intracranial germ cell tumors: a comprehensive update of the European data. Neuropediatrics 1994;25(1):26-32.

13. Christoph F, Kempkensteffen C, Weikert S, Krause H, et al.Frequent epigenetic inactivation of p53 target genes in seminomatous and nonseminomatous germ cell tumors. Cancer Lett 2007;247(1):137-42.

14. Moore BE, Banner BF, Gokden M, Woda B, et al. p53: a good diagnostic marker for intratubular germ cell neoplasia, unclassified. Appl Immunohistochem Mol Morphol 2001;9(3):203-6.

15. Chaganti RS, Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res 2000;60(6):1475-82.

16. Lutzker SG. P53 tumour suppressor gene and germ cell neoplasia.APMIS 1998;106(1):85-9.

17. Mizoguchi M, Inamura T, Shono T, Ikezaki K, et al. A comparative study of apoptosis and proliferation in germinoma and glioblastoma. Neuro Oncol 2000;2(2):96-102.

18. Burger H, Nooter K, Boersma AW, Kortland CJ, Soter G. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumor cell lines. Br J Cancer 1998;77:1562- 7.

19. Grobholz R, Zentgraf H, Khöhrmann KU, Bleyl U. Bax, Bcl-2,Fas and Fas-L antigen expression in human seminomas: correlation with the apoptotic index. APMIS 2002;110(10):724-32.

20. Arriola EL, Rodriguez-Lopez AM, Hickman JA, Chresta CM.Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumors to chemotherapy-induced apoptosis. Oncogene 1999;18(7):1457-64.

21. Burger H, Nooter K, Boersma AW, Kortland CJ, et al. Expression of p53, p21/WAF/CIP, Bcl-2,Bax, Bcl-x, and Bak in radiation- induced apoptosis in testicular germ cell tumor lines. Int J Radiat Oncol Biol Phys 1998;41(2):415-24.

22. Huddart RA, Titley J, Robertson D, Williams GT, et al. Programmed cell death in response to chemotherapeutic agents in human germ cell tumor lines. Eur J Cancer 1995;31A(5):739- 46.

23. Heidenreich A, Schenkman NS, Sesterhenn IA, Mostofi KF, et al. Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours. APMIS 1998;106(1):90-9.